# B7-H3

Source: https://nuclide.cc/targets/b7h3/  
Nuclide record `b7h3` (Target). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)"; commercial use needs a licence.

## TL;DR

B7-H3 is an immune checkpoint-like surface protein found on 60 to 70% of small-cell lung cancers and 80 to 90% of castration-resistant prostate cancers, with little on normal tissue. It is used as an ADC address, chiefly by ifinatamab deruxtecan, now in phase 3 in small-cell lung cancer; whether blocking its immune-dampening role adds anything beyond payload delivery is unresolved.

## Summary

B7-H3 (CD276) is an immune checkpoint-like molecule broadly overexpressed in solid tumours with limited normal expression; its function is debated, inhibiting T-cell activation and promoting tumour cell migration. Expression is more homogeneous than many ADC targets, found in 60-70% of small-cell lung cancer and 80-90% of castration-resistant prostate cancer by IHC, as well as head and neck and paediatric solid tumours. Ifinatamab deruxtecan (I-DXd) has shown high response rates in small-cell lung cancer and is in phase 3. B7-H3 is also pursued with radioligands and CAR-T. Whether its immune-dampening role means antibodies against it add an immunological benefit beyond payload delivery is unresolved. The simple version is a widely present tumour surface protein now used mainly as an address for ADCs.

## Fields

- Kind: Target
- Last checked: 2026-09-04
- Tags: adc-target
- Symbol: CD276
- Class: surface-antigen
- Biology: Function debated: inhibits T-cell activation, promotes tumour cell migration. Expression is more homogeneous than many ADC targets.
- Where found: Small-cell lung cancer; Prostate; Head and neck; Paediatric solid tumours

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/CD276
- Wikipedia: https://en.wikipedia.org/wiki/CD276

## Connected records

- indications: [Glioma & glioblastoma](https://nuclide.cc/indications/glioblastoma/), [Osteosarcoma](https://nuclide.cc/indications/osteosarcoma/), [Prostate cancer](https://nuclide.cc/indications/prostate/), [Small-cell lung cancer](https://nuclide.cc/indications/sclc/)
- companies: [Aktis Oncology](https://nuclide.cc/companies/aktis-oncology/)
- pathways: [Lineage plasticity & neuroendocrine transformation](https://nuclide.cc/pathways/lineage-plasticity-neuroendocrine/)
- ideas: [Alpha radioligands after ADC failure](https://nuclide.cc/ideas/idea-alpha-after-adc/)
- technologies: [Pretargeted radioimmunotherapy](https://nuclide.cc/technologies/pretargeted-radioimmunotherapy/)

---
JSON: https://nuclide.cc/api/v1/entities/b7h3.json